{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:12:41Z","timestamp":1793643161330,"version":"4.5.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.berh.2023.101841","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T07:48:07Z","timestamp":1686296887000},"page":"101841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["What is new in pharmacological treatment for osteoarthritis?"],"prefix":"10.1016","volume":"37","author":[{"given":"Halise Hande","family":"Gezer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ostor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2023.101841_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0140-6736(14)60802-3","article-title":"Osteoarthritis","volume":"386","author":"Glyn-Jones","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101841_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1136\/annrheumdis-2013-203355","article-title":"Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints","volume":"73","author":"Prieto-Alhambra","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.rehab.2016.01.006","article-title":"Risk factors and burden of osteoarthritis","volume":"59","author":"Palazzo","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"key":"10.1016\/j.berh.2023.101841_bib4","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","article-title":"Osteoarthritis","volume":"393","author":"Hunter","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101841_bib5","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/art.42089","article-title":"Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019","volume":"74","author":"Long","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib6","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101841_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcp.2019.02.037","article-title":"Osteoarthritis phenotypes and novel therapeutic targets","volume":"165","author":"Van Spil","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.berh.2023.101841_bib8","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","article-title":"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis","volume":"27","author":"Bannuru","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.berh.2023.101841_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","article-title":"Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)","volume":"21","author":"Berenbaum","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.berh.2023.101841_bib10","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.22115.1","article-title":"Recent advances in the treatment of osteoarthritis","volume":"9","author":"Gr\u00e4ssel","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.berh.2023.101841_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001660","article-title":"Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"7","author":"Kedor","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2023.101841_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/M17-1430","article-title":"Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial","volume":"168","author":"Kingsbury","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2023.101841_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/s10165-011-0506-8","article-title":"Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study","volume":"22","author":"Saviola","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.23471","article-title":"Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101841_bib15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.semarthrit.2021.04.016","article-title":"Methotrexate treatment in hand osteoarthritis refractory to usual treatments: a randomised, double-blind, placebo-controlled trial","volume":"51","author":"Ferrero","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101841_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13063-015-0602-8","article-title":"Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial","volume":"16","author":"Kingsbury","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.berh.2023.101841_bib17","first-page":"326","article-title":"Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: an open-label randomized controlled trial","volume":"46","author":"Wang","year":"2018","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.berh.2023.101841_bib18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.joca.2018.02.899","article-title":"A\u00a0randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial","volume":"26","author":"Aitken","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.berh.2023.101841_bib19","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2018-213202","article-title":"Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"77","author":"Kloppenburg","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/03009742.2019.1657493","article-title":"Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis","volume":"49","author":"Kroon","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2020-218547","article-title":"Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial","volume":"80","author":"Richette","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib22","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/art.40840","article-title":"A\u00a0phase II trial of lutikizumab, an anti-interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00296-021-04997-y","article-title":"Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and\/or anakinra treatment","volume":"42","author":"Karabulut","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2023.101841_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152070","article-title":"FDA\/Arthritis Foundation osteoarthritis drug development workshop recap: assessment of long-term benefit","volume":"56","author":"Kim","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101841_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study","volume":"61","author":"Chevalier","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101841_bib26","first-page":"1317","article-title":"Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study","volume":"32","author":"Chevalier","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/M20-0527","article-title":"Effects of interleukin-1\u03b2 inhibition on incident hip and knee replacement : exploratory analyses from a randomized, double-blind, placebo-controlled trial","volume":"173","author":"Schieker","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2023.101841_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/annrheumdis-2018-213336","article-title":"Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1\u03b1 and anti-interleukin-1\u03b2 dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis","volume":"78","author":"Kloppenburg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib29","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar3430","article-title":"A\u00a0randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee","volume":"13","author":"Cohen","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101841_bib30","first-page":"37","article-title":"Osteoarthritis pathogenesis - a complex process that involves the entire joint","volume":"7","author":"Man","year":"2014","journal-title":"J\u00a0Med Life"},{"key":"10.1016\/j.berh.2023.101841_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40744-020-00205-8","article-title":"Review article: is Wnt signaling an attractive target for the treatment of osteoarthritis?","volume":"7","author":"Lories","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.berh.2023.101841_bib32","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/art.41315","article-title":"Lorecivivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor and Wnt pathway modulator for the treatment of knee osteoarthritis: a phase II randomized trial","volume":"72","author":"Yazici","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.joca.2021.02.004","article-title":"A\u00a0Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2\/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis","volume":"29","author":"Yazici","year":"2021","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.berh.2023.101841_bib34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40744-021-00316-w","article-title":"Individual participant symptom responses to intra-articular lorecivivint in knee osteoarthritis: post hoc analysis of a phase 2B trial","volume":"8","author":"Tambiah","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.berh.2023.101841_bib35","author":"Yazici","year":"2022"},{"key":"10.1016\/j.berh.2023.101841_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128927","article-title":"Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis","volume":"74","author":"Ginnetti","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.berh.2023.101841_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00223-015-0051-0","article-title":"Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis","volume":"98","author":"Duong","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.berh.2023.101841_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12967-018-1497-4","article-title":"Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711","volume":"16","author":"Lindstr\u00f6m","year":"2018","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.berh.2023.101841_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/M19-0675","article-title":"Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized controlled trial","volume":"172","author":"Conaghan","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2023.101841_bib40","first-page":"1034","article-title":"Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis of a randomised phase 2a clinical trial","volume":"40","author":"Bihlet","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib41","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.38614","article-title":"Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial","volume":"66","author":"Lohmander","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib42","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2019.14735","article-title":"Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial","volume":"322","author":"Hochberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2023.101841_bib43","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/annrheumdis-2020-219181","article-title":"Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study","volume":"80","author":"Eckstein","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/annrheumdis-2019-216453","article-title":"Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial","volume":"79","author":"Eckstein","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib45","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1002\/art.39265","article-title":"Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging","volume":"67","author":"Eckstein","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-021-02488-w","article-title":"Efficacy and safety of sprifermin injection for knee osteoarthritis treatment: a meta-analysis","volume":"23","author":"Zeng","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101841_bib47","first-page":"65","article-title":"Differential role of transforming growth factor-beta in an osteoarthritic or a healthy joint","volume":"25","author":"van der Kraan","year":"2018","journal-title":"J\u00a0Bone Metab"},{"key":"10.1016\/j.berh.2023.101841_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ocarto.2022.100238","article-title":"Inhibition of transforming growth factor-\u03b2 in osteoarthritis. Discrepancy with reduced TGF\u03b2 signaling in normal joints","volume":"4","author":"van der Kraan","year":"2022","journal-title":"Osteoarthr Cartil Open"},{"key":"10.1016\/j.berh.2023.101841_bib49","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nm.3143","article-title":"Inhibition of TGF-\u03b2 signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis","volume":"19","author":"Zhen","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2023.101841_bib50","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.joca.2015.06.019","article-title":"Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-\u03b21 in patients with grade 3 chronic degenerative joint disease of the knee","volume":"23","author":"Cherian","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.berh.2023.101841_bib51","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s12891-017-1830-8","article-title":"Structural effects of intra-articular TGF-\u03b21 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial","volume":"18","author":"Guermazi","year":"2017","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.berh.2023.101841_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/humc.2017.249","article-title":"A\u00a0multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients","volume":"29","author":"Kim","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.berh.2023.101841_bib53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11914-015-0290-z","article-title":"Articular cartilage: structural and developmental intricacies and questions","volume":"13","author":"Decker","year":"2015","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.berh.2023.101841_bib54","article-title":"Overview of MMP-13 as a promising target for the treatment of osteoarthritis","volume":"22","author":"Hu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2023.101841_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.645842","article-title":"New trends in pharmacological treatments for osteoarthritis","volume":"12","author":"Cai","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.berh.2023.101841_bib56","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2315","article-title":"Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study","volume":"9","author":"Krzeski","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101841_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21175992","article-title":"The anti-ADAMTS-5 Nanobody(\u00ae) M6495 protects cartilage degradation ex\u00a0vivo","volume":"21","author":"Siebuhr","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2023.101841_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.joca.2010.12.004","article-title":"Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor","volume":"19","author":"Chockalingam","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"issue":"suppl 10","key":"10.1016\/j.berh.2023.101841_bib59","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody\u00ae, M6495, in healthy male subjects: a phase I, placebo-controlled, first-in-human study","volume":"71","author":"Guehring","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib60","first-page":"7670","article-title":"AMPK: implications in osteoarthritis and therapeutic targets","volume":"12","author":"Wang","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.berh.2023.101841_bib61","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/annrheumdis-2019-216713","article-title":"Metformin limits osteoarthritis development and progression through activation of AMPK signalling","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030681","article-title":"Metformin attenuates monosodium-iodoacetate-induced osteoarthritis via regulation of pain mediators and the autophagy-lysosomal pathway","volume":"10","author":"Na","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.berh.2023.101841_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15871-7","article-title":"Metformin use and the risk of total knee replacement among diabetic patients: a propensity-score-matched retrospective cohort study","volume":"12","author":"Lai","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2023.101841_bib64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-019-1915-x","article-title":"Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative-a prospective cohort study","volume":"21","author":"Wang","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101841_bib65","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1186\/s40064-016-3359-y","article-title":"Bisphosphonates therapy for osteoarthritis: a meta-analysis of randomized controlled trials","volume":"5","author":"Xing","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.berh.2023.101841_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-021-02446-6","article-title":"Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020","volume":"23","author":"Fern\u00e1ndez-Mart\u00edn","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101841_bib67","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221090297","article-title":"Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)","volume":"14","author":"Oo","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.berh.2023.101841_bib68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40268-020-00294-4","article-title":"Intramuscular clodronate in long-term treatment of symptomatic knee osteoarthritis: a randomized controlled study","volume":"20","author":"Frediani","year":"2020","journal-title":"Drugs R"},{"key":"10.1016\/j.berh.2023.101841_bib69","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s10067-017-3681-y","article-title":"Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial-The ER.O.D.E. study (ERosive Osteoarthritis and Disodium-clodronate Evaluation)","volume":"36","author":"Saviola","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib70","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00167-019-05598-w","article-title":"Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee","volume":"28","author":"M\u00fcller","year":"2020","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"10.1016\/j.berh.2023.101841_bib71","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.joca.2020.02.121","article-title":"A\u00a0multicentre randomised double-blind placebo-controlled trial of zoledronic acid for knee osteoarthritis - the zap2 trial","volume":"28","author":"Aitken","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.berh.2023.101841_bib72","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1517\/17425255.2015.1000860","article-title":"Denosumab for the treatment of osteoporosis","volume":"11","author":"Zaheer","year":"2015","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.berh.2023.101841_bib73","doi-asserted-by":"crossref","unstructured":"Wittoek R VA, Vanhaverbeke T, Elewaut D. Effect of denosumab on structure modification in erosive hand osteoarthritis: results of a 48-week, monocentric, randomized, placebo-controlled, double-blind phase 2 study and open label extension phase. Arthritis Rheumatol 20222022.","DOI":"10.1136\/annrheumdis-2023-eular.3085"},{"key":"10.1016\/j.berh.2023.101841_bib74","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.joca.2014.12.019","article-title":"Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials","volume":"23","author":"Karsdal","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.berh.2023.101841_bib75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2012-202231","article-title":"Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial","volume":"72","author":"Reginster","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib76","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2013-203989","article-title":"Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss","volume":"74","author":"Pelletier","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib77","doi-asserted-by":"crossref","first-page":"101ra93","DOI":"10.1126\/scitranslmed.3002214","article-title":"Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis","volume":"3","author":"Sampson","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.berh.2023.101841_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-022-02981-w","article-title":"Potential effects of teriparatide (PTH (1-34)) on osteoarthritis: a systematic review","volume":"25","author":"Li","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101841_bib79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41584-020-00528-4","article-title":"The evolution of nerve growth factor inhibition in clinical medicine","volume":"17","author":"Wise","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.rdc.2020.12.003","article-title":"Targeting nerve growth factor for pain management in osteoarthritis-clinical efficacy and safety","volume":"47","author":"Dietz","year":"2021","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.berh.2023.101841_bib81","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","article-title":"Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period","volume":"79","author":"Berenbaum","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101841_bib82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2019.8044","article-title":"Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial","volume":"322","author":"Schnitzer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2023.101841_bib83","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13075-022-02759-0","article-title":"Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study","volume":"24","author":"Neogi","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101841_bib84","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.39492","article-title":"When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120184","article-title":"Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis","volume":"434","author":"Brown","year":"2022","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.berh.2023.101841_bib86","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.41012","article-title":"The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb\/III double-blind, placebo-controlled, randomized clinical trial","volume":"71","author":"Dakin","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib87","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.pain.2014.03.018","article-title":"Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee","volume":"155","author":"Tiseo","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.berh.2023.101841_bib88","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.39943","article-title":"Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase II randomized, double-blind, placebo-controlled extension study","volume":"69","author":"Sanga","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101841_bib89","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1080\/03007995.2019.1653068","article-title":"Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies","volume":"35","author":"Kelly","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.berh.2023.101841_bib90","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sjpain.2017.07.021","article-title":"A\u00a0randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis","volume":"17","author":"Mayorga","year":"2017","journal-title":"Scand J Pain"},{"key":"10.1016\/j.berh.2023.101841_bib91","article-title":"Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan","volume":"13","author":"Lu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2023.101841_bib92","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12891-018-2143-2","article-title":"A\u00a0protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients - zap2","volume":"19","author":"Aitken","year":"2018","journal-title":"BMC Muscoskel Disord"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422300027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422300027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:50Z","timestamp":1761499430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169422300027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S152169422300027X"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101841","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is new in pharmacological treatment for osteoarthritis?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101841"}}